Adults at Heart Risk Saw LDL Cholesterol Fall Sharply on a New Daily Pill

CATEGORY: HEART & CIRCULATION

For a decade, the most powerful cholesterol drugs have come with a needle attached. If statins didn’t get your LDL low enough, the next step up meant injections. That barrier just fell. In a 52-week trial of 2,909 adults with heart disease or at high risk of it, a once-daily tablet called enlicitide lowered LDL cholesterol by 57%, while LDL in the placebo group drifted slightly up.¹ The gap between the groups was about 56 percentage points. In August 2026, the FDA approved the drug under the brand name Lipfendra, making it the first pill in its class.

A Protein Blocker Shrunk Down to Tablet Size

Your liver clears LDL, the so-called bad cholesterol, out of your blood using receptors on its surface. A protein called PCSK9 destroys those receptors. Block the protein, and the liver keeps more receptors, pulls in more LDL, and blood levels drop. Injectable PCSK9 inhibitors have worked this way since 2015, but they’re antibodies, which digest like food if swallowed. Enlicitide is a much smaller engineered molecule that survives the trip. That’s the whole innovation. Same target, no needle.

Fifty-Two Weeks Against Placebo

The trial enrolled adults who either had already suffered a major cardiovascular event or were at elevated risk of a first one, with LDL still at 55 mg/dL or higher despite that history. Their average LDL at the start was 96 mg/dL. A 2-to-1 random split, made before anything else was known about each participant, determined who got the 20 mg tablet and who got placebo. Merck funded and ran the study. By week 24, LDL had fallen 57.1% in the enlicitide group and risen 3.0% with placebo. Picture a $100 balance cut to $43. The reduction held through week 52, and the drug also lowered two related blood fats, apolipoprotein B and lipoprotein(a). Side effects were about as common with the drug as with placebo.

It Also Beat the Pills It Will Compete With

A companion trial answered the more practical question: how does enlicitide compare with the non-statin pills doctors already reach for? Among 301 statin-treated adults randomized head to head for 56 days, enlicitide cut LDL by 64.6%, while ezetimibe managed 27.8%, bempedoic acid 6.3%, and the two combined 36.5%.² No other cholesterol pill came close. What no one has yet shown is the outcome that actually matters: fewer heart attacks, strokes and deaths. LDL is a marker, though an unusually well-validated one, and the approval rests on the LDL numbers. A separate large trial testing enlicitide against those hard outcomes is under way, and until it reads out, the honest claim for this pill is a very large LDL drop with needle-free convenience.

Key Takeaways

• Enlicitide, the first oral PCSK9 inhibitor, cut LDL cholesterol 57% over a year among 2,909 trial participants and was FDA-approved in August 2026 as Lipfendra.
• Head to head, it lowered LDL far more than ezetimibe, bempedoic acid, or both together.
• Its effect on heart attacks and strokes hasn’t been shown yet; a dedicated outcomes trial is still running.

References

1. Navar AM, Mikhailova E, Catapano AL, et al. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. The New England Journal of Medicine. 2026;394(6):529–539. link
2. Catapano AL, Mikhailova E, Navar AM, et al. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. Journal of the American College of Cardiology. 2026;88(3):340–352. link